A Message from the President
As 2025 draws to a close, I am humbled by the resilience of our community. Throughout the year, many of us faced disruption in our clinics and labs with the uncertain and shifting funding paradigm. However, thanks to each of you, 2025 was a year of remarkable progress for our community.
Like our members, SITC’s leadership remained steadfast and future focused. At the biotech strategic meeting at the NYSE, we explored opportunities to advance TCEs, bispecifics and in vivo CAR T approaches. Our summit on expanding access to cell therapies for solid tumors brought together experts to examine pathways into the community clinics for these emerging indications. We expanded the conversation further at our Leveraging Biomarkers Workshop, underscoring the urgent need to accelerate biomarker discovery and integration. And this year, we proudly saw the full Next Wave of Immuno-Oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC) series published in the Journal for ImmunoTherapy of Cancer (JITC), marking a significant contribution to the field and a cornerstone for future innovation.
Each of these initiatives directly advances SITC’s mission to bring 100 novel agents to patients by 2034 and with 13 novel agents approved in the last two years, we’re well on our way to achieving that goal. Coupled with expanding modalities is SITC’s vision to see these lifesaving therapies approved in earlier lines of treatment. This year, SITC held many programs focused on perioperative immuno-oncology. Notably, over 31% of FDA approvals involving immuno-oncology (so far) this year were for neoadjuvant and/or adjuvant indications. This momentum speaks not only to the scientific advances occurring across our community but also to the promise these therapies hold for patients in the years ahead.
As we close out the year, I am reminded that the progress we saw in 2025 is a direct reflection of the dedication and passion of our members, volunteers, partners and staff.
Thank you for your continued commitment to SITC and to the field of cancer immunotherapy. I look forward to all that we will achieve together in 2026.
Program Spotlight
CANCER IMMUNOTHERAPY WINTER SCHOOL
Last Chance to Save on Registration for 2026 Cancer Immunotherapy
Winter School!
Cancer Immunotherapy Winter School, Feb. 16–18, 2026 in Boston, MA or virtually, offers essential IO education, the latest advancements in the field. There are ample opportunities to develop new relationships with faculty, including program organizers Kristin Anderson, PhD – University of Virginia, Chrystal Paulos, PhD – Winship Cancer Institute at Emory University, Ryan J. Sullivan, MD – Harvard Medical School, Massachusetts General Hospital and program advisor Daniel J. Powell Jr., PhD – University of Pennsylvania.
In addition, you will have opportunities to expand your professional network with peers, faculty and other thought leaders through small group breakout sessions.
Register before Dec. 20 to save up to $250 off regular rates.